semaglutide cardiovascular outcomes news today 2025 Wegovy confers reductions in risk, regardless of weight loss Oral Semaglutide Reduces Cardiovascular Events

Semaglutide 2.4 mg (Wegovy) is a GLP-1 receptor agonist that reduces appetite and food intake via hormonal pathways

Ozempic for weight loss falls into this same category

They want better energy, improved confidence, stronger body composition and the ability to enjoy an active Gulf Coast lifestyle

With respect to the study, as the authors acknowledge, the study has limitations, including potential confounding by indication and by other factors, the company said in a statement to CNN

10.1097/MD.0000000000026751 29 ChestowskaB.Baraczyk-KuzmaA.Kuzma-KozakiewiczM

A glass of commercial grapefruit juice can run 90+ calories with minimal fiber